Evidence map›Paper›PMID 19018278›Full record

ArticlePloS one2008

Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay.

Robert Grützmann, Bela Molnar, Christian Pilarsky, Jens K Habermann, Peter M Schlag, Hans D Saeger, Stephan Miehlke, Thomas Stolz, Fabian Model, Uwe J Roblick and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
183citing papers in PubMed, 12 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

183 citing papers in PubMed, 12 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Serum tests for colorectal cancer screening.Molecular diagnosis & therapy · 2011
    Pooled it
  13. Epi proColonMolecular diagnosis & therapy · 2020
    Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

123 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Robert GrützmannDepartment of Visceral-, Thoracic- and Vascular Surgery, University Hospital Carl Gustav Carus Dresden, Dresden, Germany. Robert.Gruetzmann@uniklinikum-dresden.de
Bela Molnar
Christian Pilarsky
Jens K Habermann
Peter M Schlag
Hans D Saeger
Stephan Miehlke
Thomas Stolz
Fabian Model
Uwe J Roblick
Hans-Peter Bruch
Rainer Koch
Volker Liebenberg
Theo Devos
Xiaoling Song
Robert H Day
Andrew Z Sledziewski
Catherine Lofton-Day

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is the second leading cause of cancer deaths despite the fact that detection of this cancer in early stages results in over 90% survival rate. Currently less than 45% of at-risk individuals in the US are screened regularly, exposing a need for better screening tests. We performed two case-control studies to validate a blood-based test that identifies methylated DNA in plasma from all stages of CRC. METHODOLOGY/PRINCIPAL

findingsUsing a PCR assay for analysis of Septin 9 (SEPT9) hypermethylation in DNA extracted from plasma, clinical performance was optimized on 354 samples (252 CRC, 102 controls) and validated in a blinded, independent study of 309 samples (126 CRC, 183 controls). 168 polyps and 411 additional disease controls were also evaluated. Based on the training study SEPT9-based classification detected 120/252 CRCs (48%) and 7/102 controls (7%). In the test study 73/126 CRCs (58%) and 18/183 control samples (10%) were positive for SEPT9 validating the training set results. Inclusion of an additional measurement replicate increased the sensitivity of the assay in the testing set to 72% (90/125 CRCs detected) while maintaining 90% specificity (19/183 for controls). Positive rates for plasmas from the other cancers (11/96) and non-cancerous conditions (41/315) were low. The rate of polyp detection (>1 cm) was approximately 20%. CONCLUSIONS/SIGNIFICANCE: Analysis of SEPT9 DNA methylation in plasma represents a straightforward, minimally invasive method to detect all stages of CRC with potential to satisfy unmet needs for increased compliance in the screening population. Further clinical testing is warranted.

Indexed as

DNA MethylationAdultAgedAlgorithmsCase-Control StudiesColorectal NeoplasmsFemaleGTP PhosphohydrolasesHumansMaleMass ScreeningMiddle AgedPolymerase Chain ReactionSensitivity and SpecificitySeptinsTreatment OutcomeGTP PhosphohydrolasesSEPTIN9 protein, humanSeptins

Identifiers

PMID19018278
PMCPMC2582436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.